



Network Notification

Notice Date: August 1, 2026
To: Senior Care Options and One Care Providers
From: Commonwealth Care Alliance® (CCA)
Subject: September 2026 Updates to CCA's Medical Specialty Drug Policies
Effective Date: September 1, 2026

Summary

Effective September 1, 2026, Commonwealth Care Alliance® (CCA) is updating select Medical Specialty Drug Policies for our Senior Care Options (SCO) and One Care plans. To help you prepare, this communication outlines the policies that are changing and where to find additional information. We encourage you to review the "Summary of Changes" section within each policy to understand any updates that may affect the care of your CCA-covered patients. Medical Specialty Drug Policies can be accessed here: [Medical Necessity Guidelines | Commonwealth Care Alliance MA](#)

Bimonthly Policy Updates

Every other month you will receive a consolidated network notification summarizing all recent medical specialty drug policy changes. This helps you stay informed and up to date with minimal effort.

How to Use This Notification:

- Review the list of updated policies located here: [Medical Necessity Guidelines | Commonwealth Care Alliance MA](#)
- Note the effective date and the specific plans impacted by each policy.

Medical Specialty Drug Policy Updates

Policy	New or Revised
Alzheimer's Disease – Amyloid Beta-Directed Antibodies – Kisunla UM Medical	Revised
Alzheimer's Disease – Amyloid Beta-Directed Antibodies – Leqembi Intravenous	New
Antiemetics – Palonosetron Intravenous UM Medical	Revised
Bone Modifiers – Denosumab Products (Prolia) UM Medical	Revised
Bone Modifiers – Denosumab Products (Xgeva) UM Medical	Revised
Chemoprotective Agent – Pedmark UM Medical	Revised
Colony Stimulating Factors – Filgrastim Products UM Medical	Revised
Complement Inhibitors – PiaSky Utilization Management (UM) Medical	Revised
Coronavirus Disease – Evusheld UM Medical	Revised

Policy	New or Revised
Coronavirus Disease – Veklury UM	Revised
Corticosteroids (Intraarticular) – Zilretta UM Medical	Revised
Crysvita UM Medical	Revised
Dermatology – Gene Therapy – Vyjuvek UM Medical	Revised
Dermatology – Gene Therapy – Zevaskyn UM Medical	Revised
Dermatology – Ycanth UM Medical	Revised
Erythropoiesis-Stimulating Agents – Mircera UM Medical	Revised
Gonadotropin-Releasing Hormone Agonists – Lupron Depot UM Medical	Revised
Gout – Krystexxa UM Medical	Revised
Graft-Versus-Host-Disease – Niktimvo UM Medical	Revised
Graft-Versus-Host-Disease – Ryoncil UM	Revised
Hematology – Cablivi UM Medical	Revised
Hematology – Enjaymo UM Medical	Revised
Hematology – Fibrinogen Products UM Medical	Revised
Hematology – Gene Therapy – Casgevy UM Medical	Revised
Hematology – Gene Therapy – Lyfgenia UM Medical	Revised
Hematology – Gene Therapy – Zynteglo UM Medical	Revised
Hematology – Reblozyl UM Medical	Revised
Hematology – Ryplazim UM Medical	Revised
Hematology – Rytelo UM Medical	Revised
Hemophilia – Altuviiio UM Medical	Revised
Hemophilia – Factor IX Products UM Medical	Revised
Hemophilia – Factor VIII Products UM Medical	Revised
Hemophilia – Gene Therapy – Hemgenix UM Medical	Revised
Hemophilia – Non-Factor Routine Prophylaxis Products – Hemlibra UM Medical	Revised
Hereditary Angioedema – Andembry UM Medical	Revised
Human Immunodeficiency Virus – Apretude UM Medical	Revised
Human Immunodeficiency Virus – Cabenuva UM Medical	Revised
Human Immunodeficiency Virus – Sunlenca UM Medical	Revised
Hyperlipidemia – PCSK9 Inhibitors – Leqvio UM Medical	Revised
Immune Globulin – Atgam UM Medical	Revised
Immune Globulin – Cytogam UM Medical	Revised
Immune Globulin – Intravenous UM Medical	Revised
Immune Globulin – Subcutaneous UM Medical	Revised
Immunologicals – Fasenra UM Medical	Revised
Immunologicals – Nucala UM Medical	Revised
Inflammatory Conditions – Ilaris UM Medical	Revised
Inflammatory Conditions – Ilumya UM Medical	Revised
Inflammatory Conditions – Simponi Aria UM Medical	Revised
Inflammatory Conditions – Skyrizi Intravenous UM Medical	Revised
Inflammatory Conditions – Spevigo Intravenous UM Medical	Revised

Policy	New or Revised
Iron Replacement – Ferumoxytol UM Medical	Revised
Iron Replacement – INFeD – UM Medical	Revised
Iron Replacement – Injectafer – UM Medical	Revised
Iron Replacement – Iron Sucrose UM Medical	Revised
Iron Replacement – Monoferric – UM Medical	Revised
Iron Replacement – Sodium Ferric Gluconate UM Medical	Revised
Lupus – Saphnelo Intravenous UM Medical	Revised
Metabolic Disorders – Imcivree UM Medical	Revised
Multiple Sclerosis (Injectable – CD20-Directed Cytolytic Antibody) – Ocrevus Intravenous UM Medical	New
Muscular Dystrophy – Amondys 45 UM Medical	Revised
Neurology – Gene Therapy – Lenmeldy UM Medical	Revised
Neurology – Imaavy UM Medical	Revised
Neurology – Rystiggo UM Medical	Revised
Neurology – Vyvgart Hytrulo UM Medical	Revised
Neurology – Vyvgart Intravenous UM Medical	Revised
Oncology (Injectable – Antibody-Drug Conjugate – CD123) – Decnupaz UM Medical	New
Oncology (Injectable – Antibody-Drug Conjugate – CD22) – Besponsa UM Medical	Revised
Oncology (Injectable – Antibody-Drug Conjugate – HER2) – Enhertu UM Medical	Revised
Oncology (Injectable – Antibody-Drug Conjugate – Trop2) – Datroway UM Medical	Revised
Oncology (Injectable – Antibody-Drug Conjugate – Trop2) – Trodelvy UM Medical	Revised
Oncology (Injectable – Anti-GD2 Antibody) – Danyelza UM Medical	Revised
Oncology (Injectable – Anti-GD2 Antibody) – Unituxin UM Medical	Revised
Oncology (Injectable – Asparaginase) – Asparlas UM Medical	Revised
Oncology (Injectable – Asparaginase) – Oncaspar UM Medical	Revised
Oncology (Injectable – Bispecific – CD20-Directed) – Columvi UM Medical	Revised
Oncology (Injectable – Bispecific – CD20-Directed) – Epkinly UM Medical	Revised
Oncology (Injectable – Bispecific – CD20-Directed) – Lunsumio UM Medical	New
Oncology (Injectable – Bispecific – CD20-Directed) – Lunsumio Velo UM Medical	New
Oncology (Injectable – CAR-T) – Breyanzi UM Medical	Revised
Oncology (Injectable – CD20-Directed Antibody) – Rituxan Hycela UM Medical	New
Oncology (Injectable – CTLA-4 Antibody) – Yervoy UM Medical	Revised
Oncology (Injectable – HER2 Antagonist) – Trastuzumab Products UM Medical	Revised
Oncology (Injectable – Histone Deacetylase Inhibitor) – Romidepsin Products UM Medical	Revised
Oncology (Injectable – Microtubule Inhibitor) – Ixempra UM Medical	Revised
Oncology (Injectable – mTOR Inhibitor) – Fyarro UM Medical	Revised
Oncology (Injectable – Programmed Death Ligand-1) – Unloxcyt UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Jemperli UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Keytruda Intravenous UM Medical	Revised

Policy	New or Revised
Oncology (Injectable – Programmed Death Receptor-1) – Keytruda Qlex UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Libtayo UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Loqtorzi UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Opdivo Qvantig UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Opdualag UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Tevimbra UM Medical	Revised
Oncology (Injectable – Programmed Death-Ligand 1) – Bavencio UM Medical	Revised
Oncology (Injectable – Programmed Death-Ligand 1) – Imfinzi UM Medical	Revised
Oncology (Injectable – Programmed Death-Ligand 1) – Tecentriq Hybreza UM Medical	Revised
Oncology (Injectable – Programmed Death-Ligand 1) – Tecentriq Intravenous UM Medical	Revised
Oncology (Injectable – Topoisomerase Inhibitor) – Onivyde UM Medical	Revised
Oncology (Injectable – Topoisomerase Inhibitor) – Topotecan Products UM Medical	Revised
Oncology (Injectable) – Amtagvi UM Medical	Revised
Oncology (Injectable) – Azedra UM Medical	Revised
Oncology (Injectable) – Bevacizumab Products UM Medical	Revised
Oncology (Injectable) – Bizengri UM Medical	Revised
Oncology (Injectable) – Carmustine Products UM Medical	Revised
Oncology (Injectable) – Cyramza UM Medical	Revised
Oncology (Injectable) – Elahere UM Medical	Revised
Oncology (Injectable) – Elzonris UM Medical	Revised
Oncology (Injectable) – Fulvestrant UM Medical	Revised
Oncology (Injectable) – Gonadotropin-Releasing Hormone Analogs UM Medical	Revised
Oncology (Injectable) – Imdelltra UM Medical	Revised
Oncology (Injectable) – Kimmtrak UM Medical	Revised
Oncology (Injectable) – Levoleucovorin Products UM Medical	Revised
Oncology (Injectable) – Margenza UM Medical	Revised
Oncology (Injectable) – Mylotarg UM Medical	Revised
Oncology (Injectable) – Padcev UM Medical	Revised
Oncology (Injectable) – Pemetrexed Products UM Medical	Revised
Oncology (Injectable) – Polivy UM Medical	Revised
Oncology (Injectable) – Portrazza UM Medical	Revised
Oncology (Injectable) – Pralatrexate UM Medical	Revised
Oncology (Injectable) – Proleukin UM Medical	Revised
Oncology (Injectable) – Sylvant UM Medical	Revised
Oncology (Injectable) – Temozolomide Intravenous UM Medical	Revised
Oncology (Injectable) – Thiotepa Products UM Medical	Revised
Oncology (Injectable) – Trabectedin Products UM Medical	New
Oncology (Injectable) – Zynlonta UM Medical	Revised
Oncology (Intravesical) – Zusduri UM Medical	Revised

Policy	New or Revised
Oncology (Other) – Jelmyto UM Medical	Revised
Ophthalmology – Durysta UM Medical	Revised
Ophthalmology – iDose TR UM Medical	Revised
Ophthalmology – Tepezza UM Medical	Revised
Ophthalmology – Vascular Endothelial Growth Factor Inhibitors – Aflibercept Products UM Medical	Revised
Ophthalmology – Vascular Endothelial Growth Factor Inhibitors – Ranibizumab Products UM Medical	Revised
Pompe Disease – Enzyme Replacement Therapy – Lumizyme UM Medical	Revised
Pompe Disease – Enzyme Replacement Therapy – Nexviazyme UM Medical	Revised
Pompe Disease – Enzyme Replacement Therapy – Pombiliti UM Medical	Revised
Psychiatry – Zulresso UM Medical	Revised
Repository Corticotropin – Acthar Gel UM Medical	Revised
Repository Corticotropin – Cortrophin Gel UM Medical	Revised
Scenesse UM Medical	Revised
Sickle Cell Disease – Adakveo UM Medical	Revised
Somatostatin Analogs – Octreotide Long-Acting Products UM Medical	Revised
Spinal Muscular Atrophy – Gene Therapy – Itvisma UM Medical	New
Spinal Muscular Atrophy – Gene Therapy – Zolgensma UM Medical	Revised
Transplantation – Grafapex UM Medical	Revised
Transplantation – Yartemlea UM Medical	New
Uplizna UM Medical	Revised

Questions?

For more information, please contact CCA Provider Services at 1-866-420-9332. Hours of availability are 8:00 a.m. to 5:00 p.m. Monday through Wednesday and Friday, and on Thursdays from 8:30 a.m. to 5:00 p.m., Eastern Time (ET).

Thank you for your partnership and for the care you provide for our members.

MA-Multi-P-5877597